Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease [8]

American Journal of Gastroenterology

Volumn 96, Issue 2, 2001, Pages 607-608

  Adinolfi, Luigi E ^a   Mangoni, Emanuele Durante ^a   Andreana, Augusto ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOMYSIUM ANTIBODY; GLIADIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AUTOIMMUNITY; CASE REPORT; CELIAC DISEASE; CHRONIC ACTIVE HEPATITIS; CLINICAL FEATURE; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG INDICATION; DRUG RESPONSE; HEPATITIS C; HISTOLOGY; HUMAN; LETTER; MALE; PARALYTIC ILEUS; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM; TH1 CELL; TH2 CELL; TREATMENT INDICATION; TREATMENT OUTCOME; VITAMIN K DEFICIENCY; WEIGHT REDUCTION;

EID: 0035120252     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02367-4     Document Type: Letter

References (5)

1. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease
2. Cytokine-producing cells in peripheral blood of children with coeliac disease secrete cytokines with a type 1 profile
3. Celiac disease during interferon treatment
4. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
5. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile